503 results on '"Goldin, Jonathan G."'
Search Results
2. Multi‐scale, domain knowledge‐guided attention + random forest: a two‐stage deep learning‐based multi‐scale guided attention models to diagnose idiopathic pulmonary fibrosis from computed tomography images
- Author
-
Yu, Wenxi, Zhou, Hua, Choi, Youngwon, Goldin, Jonathan G, Teng, Pangyu, Wong, Weng Kee, McNitt‐Gray, Michael F, Brown, Matthew S, and Kim, Grace Hyun J
- Subjects
Medical and Biological Physics ,Engineering ,Physical Sciences ,Biomedical Engineering ,Bioengineering ,Lung ,Rare Diseases ,Biomedical Imaging ,Machine Learning and Artificial Intelligence ,Networking and Information Technology R&D (NITRD) ,Autoimmune Disease ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Humans ,Aged ,Random Forest ,Deep Learning ,Idiopathic Pulmonary Fibrosis ,Lung Diseases ,Interstitial ,Tomography ,X-Ray Computed ,Retrospective Studies ,attention models ,computed tomography ,deep learning ,domain knowledge ,idiopathic pulmonary fibrosis ,machine learning ,medical imaging ,Other Physical Sciences ,Oncology and Carcinogenesis ,Nuclear Medicine & Medical Imaging ,Biomedical engineering ,Medical and biological physics - Abstract
BackgroundIdiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and usually fatal lung disease of unknown reasons, generally affecting the elderly population. Early diagnosis of IPF is crucial for triaging patients' treatment planning into anti-fibrotic treatment or treatments for other causes of pulmonary fibrosis. However, current IPF diagnosis workflow is complicated and time-consuming, which involves collaborative efforts from radiologists, pathologists, and clinicians and it is largely subject to inter-observer variability.PurposeThe purpose of this work is to develop a deep learning-based automated system that can diagnose subjects with IPF among subjects with interstitial lung disease (ILD) using an axial chest computed tomography (CT) scan. This work can potentially enable timely diagnosis decisions and reduce inter-observer variability.MethodsOur dataset contains CT scans from 349 IPF patients and 529 non-IPF ILD patients. We used 80% of the dataset for training and validation purposes and 20% as the holdout test set. We proposed a two-stage model: at stage one, we built a multi-scale, domain knowledge-guided attention model (MSGA) that encouraged the model to focus on specific areas of interest to enhance model explainability, including both high- and medium-resolution attentions; at stage two, we collected the output from MSGA and constructed a random forest (RF) classifier for patient-level diagnosis, to further boost model accuracy. RF classifier is utilized as a final decision stage since it is interpretable, computationally fast, and can handle correlated variables. Model utility was examined by (1) accuracy, represented by the area under the receiver operating characteristic curve (AUC) with standard deviation (SD), and (2) explainability, illustrated by the visual examination of the estimated attention maps which showed the important areas for model diagnostics.ResultsDuring the training and validation stage, we observe that when we provide no guidance from domain knowledge, the IPF diagnosis model reaches acceptable performance (AUC±SD = 0.93±0.07), but lacks explainability; when including only guided high- or medium-resolution attention, the learned attention maps are not satisfactory; when including both high- and medium-resolution attention, under certain hyperparameter settings, the model reaches the highest AUC among all experiments (AUC±SD = 0.99±0.01) and the estimated attention maps concentrate on the regions of interests for this task. Three best-performing hyperparameter selections according to MSGA were applied to the holdout test set and reached comparable model performance to that of the validation set.ConclusionsOur results suggest that, for a task with only scan-level labels available, MSGA+RF can utilize the population-level domain knowledge to guide the training of the network, which increases both model accuracy and explainability.
- Published
- 2023
3. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography.
- Author
-
Khanna, Dinesh, Distler, Oliver, Cottin, Vincent, Brown, Kevin K, Chung, Lorinda, Goldin, Jonathan G, Matteson, Eric L, Kazerooni, Ella A, Walsh, Simon Lf, McNitt-Gray, Michael, and Maher, Toby M
- Subjects
Systemic sclerosis ,high-resolution computed tomography ,imaging ,interstitial lung disease ,progressive fibrosing ,radiation ,Autoimmune Disease ,Lung Cancer ,Neurodegenerative ,Lung ,Brain Disorders ,Rare Diseases ,Biomedical Imaging ,Bioengineering ,Clinical Research ,Prevention ,Cancer ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Respiratory - Abstract
Patients with systemic sclerosis are at high risk of developing systemic sclerosis-associated interstitial lung disease. Symptoms and outcomes of systemic sclerosis-associated interstitial lung disease range from subclinical lung involvement to respiratory failure and death. Early and accurate diagnosis of systemic sclerosis-associated interstitial lung disease is therefore important to enable appropriate intervention. The most sensitive and specific way to diagnose systemic sclerosis-associated interstitial lung disease is by high-resolution computed tomography, and experts recommend that high-resolution computed tomography should be performed in all patients with systemic sclerosis at the time of initial diagnosis. In addition to being an important screening and diagnostic tool, high-resolution computed tomography can be used to evaluate disease extent in systemic sclerosis-associated interstitial lung disease and may be helpful in assessing prognosis in some patients. Currently, there is no consensus with regards to frequency and scanning intervals in patients at risk of interstitial lung disease development and/or progression. However, expert guidance does suggest that frequency of screening using high-resolution computed tomography should be guided by risk of developing interstitial lung disease. Most experienced clinicians would not repeat high-resolution computed tomography more than once a year or every other year for the first few years unless symptoms arose. Several computed tomography techniques have been developed in recent years that are suitable for regular monitoring, including low-radiation protocols, which, together with other technologies, such as lung ultrasound and magnetic resonance imaging, may further assist in the evaluation and monitoring of patients with systemic sclerosis-associated interstitial lung disease. A video abstract to accompany this article is available at: https://www.globalmedcomms.com/respiratory/Khanna/HRCTinSScILD.
- Published
- 2022
4. Detection and Early Referral of Patients With Interstitial Lung Abnormalities An Expert Survey Initiative
- Author
-
Hunninghake, Gary M, Goldin, Jonathan G, Kadoch, Michael A, Kropski, Jonathan A, Rosas, Ivan O, Wells, Athol U, Yadav, Ruchi, Lazarus, Howard M, Abtin, Fereidoun G, Corte, Tamera J, de Andrade, Joao A, Johannson, Kerri A, Kolb, Martin R, Lynch, David A, Oldham, Justin M, Spagnolo, Paolo, Strek, Mary E, Tomassetti, Sara, Washko, George R, White, Eric S, Group, ILA Study, Abtin, Fereidoun, Antoniou, Katerina, Blackwell, Timothy, Brown, Kevin, Chung, Jonathan, Corte, Tamera, Crestani, Bruno, Crossno, Peter, Culver, Daniel, de Andrade, Joao, Deveraj, Anand, Flaherty, Kevin, Gudmundsson, Gunnar, Hatabu, Hiroto, Jacob, Joe, Johansson, Kerri, Kanne, Jeff, Kazerooni, Ella, Kolb, Martin, Lynch, David, Maher, Toby, Martinez, Fernando, Morais, Antonio, Nathan, Steven D, Noth, Imre, Oldham, Justin, Podolanczuk, Anna, Poletti, Venerino, Ravaglia, Claudia, Renzoni, Elizabetta, Richeldi, Luca, Rubin, Geoffrey, Ryerson, Chris, Sahoo, Debasis, Suh, Rob, Sverzellati, Nicola, Valeyre, Dominique, Walsh, Simon, and Washko, George
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Prevention ,Biomedical Imaging ,Lung ,Clinical Research ,4.4 Population screening ,Detection ,screening and diagnosis ,Respiratory ,Disease Progression ,Early Diagnosis ,Female ,Humans ,Lung Diseases ,Interstitial ,Male ,Pulmonologists ,Radiologists ,Referral and Consultation ,Respiratory Function Tests ,Surveys and Questionnaires ,Tomography ,X-Ray Computed ,CT ,fi brosis ,interstitial lung abnormalities ,interstitial lung disease ,survey ,ILA Study Group ,fibrosis ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundInterstitial lung abnormalities (ILA) may represent undiagnosed early-stage or subclinical interstitial lung disease (ILD). ILA are often observed incidentally in patients who subsequently develop clinically overt ILD. There is limited information on consensus definitions for, and the appropriate evaluation of, ILA. Early recognition of patients with ILD remains challenging, yet critically important. Expert consensus could inform early recognition and referral.Research questionCan consensus-based expert recommendations be identified to guide clinicians in the recognition, referral, and follow-up of patients with or at risk of developing early ILDs?Study design and methodsPulmonologists and radiologists with expertise in ILD participated in two iterative rounds of surveys. The surveys aimed to establish consensus regarding ILA reporting, identification of patients with ILA, and identification of populations that might benefit from screening for ILD. Recommended referral criteria and follow-up processes were also addressed. Threshold for consensus was defined a priori as ≥ 75% agreement or disagreement.ResultsFifty-five experts were invited and 44 participated; consensus was reached on 39 of 85 questions. The following clinically important statements achieved consensus: honeycombing and traction bronchiectasis or bronchiolectasis indicate potentially progressive ILD; honeycombing detected during lung cancer screening should be reported as potentially significant (eg, with the Lung CT Screening Reporting and Data System "S-modifier" [Lung-RADS; which indicates clinically significant or potentially significant noncancer findings]), recommending referral to a pulmonologist in the radiology report; high-resolution CT imaging and full pulmonary function tests should be ordered if nondependent subpleural reticulation, traction bronchiectasis, honeycombing, centrilobular ground-glass nodules, or patchy ground-glass opacity are observed on CT imaging; patients with honeycombing or traction bronchiectasis should be referred to a pulmonologist irrespective of diffusion capacity values; and patients with systemic sclerosis should be screened with pulmonary function tests for early-stage ILD.InterpretationGuidance was established for identifying clinically relevant ILA, subsequent referral, and follow-up. These results lay the foundation for developing practical guidance on managing patients with ILA.
- Published
- 2022
5. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
- Author
-
Corte, Tamera J, Lancaster, Lisa, Swigris, Jeffrey J, Maher, Toby M, Goldin, Jonathan G, Palmer, Scott M, Suda, Takafumi, Ogura, Takashi, Minnich, Anne, Zhan, Xiaojiang, Tirucherai, Giridhar S, Elpers, Brandon, Xiao, Hong, Watanabe, Hideaki, Smith, R Adam, Charles, Edgar D, and Fischer, Aryeh
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Rare Diseases ,Clinical Research ,Clinical Trials and Supportive Activities ,Autoimmune Disease ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Respiratory ,Adult ,Humans ,Idiopathic Pulmonary Fibrosis ,Lysophospholipids ,Receptors ,Lysophosphatidic Acid ,Vital Capacity ,interstitial fibrosis ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment discontinuation because of adverse events is common. Fibrotic diseases such as these can be mediated by lysophosphatidic acid (LPA), which signals via six LPA receptors (LPA1-6). Signalling via LPA1 appears to be fundamental in the pathogenesis of fibrotic diseases. BMS-986278, a second-generation LPA1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD. This phase 2, randomised, double-blind, placebo-controlled, parallel-group, international trial will include adults with IPF or PF-ILD. The trial will consist of a 42-day screening period, a 26-week placebo-controlled treatment period, an optional 26-week active-treatment extension period, and a 28-day post-treatment follow-up. Patients in both the IPF (n=240) and PF-ILD (n=120) cohorts will be randomised 1:1:1 to receive 30 mg or 60 mg BMS-986278, or placebo, administered orally two times per day for 26 weeks in the placebo-controlled treatment period. The primary endpoint is rate of change in per cent predicted forced vital capacity from baseline to week 26 in the IPF cohort. This study will be conducted in accordance with Good Clinical Practice guidelines, Declaration of Helsinki principles, and local ethical and legal requirements. Results will be reported in a peer-reviewed publication. NCT04308681.
- Published
- 2021
6. The Extent and Diverse Trajectories of Longitudinal Changes in Rheumatoid Arthritis Interstitial Lung Diseases Using Quantitative HRCT Scores.
- Author
-
Lee, Jeong Seok, Kim, Grace-Hyun J, Ha, You-Jung, Kang, Eun Ha, Lee, Yun Jong, Goldin, Jonathan G, and Lee, Eun Young
- Subjects
interstitial lung disease ,quantitative score ,rheumatoid arthritis ,Clinical Sciences - Abstract
We aimed to validate quantitative high-resolution computed tomography (HRCT) imaging analyses of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients, and to delineate a broad spectrum of annual longitudinal changes of ILD severity in the RA-ILD cohorts. Retrospective cohort 1 (n = 26) had matched PFT results and prospective cohort 2 (n = 34) were followed for over two years with baseline serum specimen. Automated quantitative analysis of HRCT was expressed as the extent of ground-glass opacity, lung fibrosis, honeycombing, and their summation-the total extent of quantitative ILD (QILD). Higher QILD score was associated with lower pulmonary function especially for DLCO% (ρ = -0.433, p = 0.027). Higher serum level of Krebs von den Lungen 6 were significantly associated with high QILD scores (ρ = 0.400, p = 0.026). Regarding QILD score changes in whole lung, even a single point increase was significantly associated with interval progression detected by the radiologist. Four distinct patterns (improvement, worsening, convex-like, and concave-like) during the 24 months were described by QILD scores. Prolonged disease duration of ILD at baseline was significantly associated with worsening of QILD scores. QILD has the potential to reliably evaluate the dynamic severity changes in patients with RA-ILD.
- Published
- 2021
7. Radiologist and Radiology Practice Wellbeing: A Report of the 2023 ARRS Wellness Summit
- Author
-
Azour, Lea, Goldin, Jonathan G., and Kruskal, Jonathan B.
- Published
- 2024
- Full Text
- View/download PDF
8. End‐to‐end domain knowledge‐assisted automatic diagnosis of idiopathic pulmonary fibrosis (IPF) using computed tomography (CT)
- Author
-
Yu, Wenxi, Zhou, Hua, Goldin, Jonathan G, Wong, Weng Kee, and Kim, Grace Hyun J
- Subjects
Medical and Biological Physics ,Engineering ,Physical Sciences ,Biomedical Engineering ,Bioengineering ,Rare Diseases ,Autoimmune Disease ,Clinical Research ,Biomedical Imaging ,Lung ,Respiratory ,Humans ,Idiopathic Pulmonary Fibrosis ,Lung Diseases ,Interstitial ,Prospective Studies ,Retrospective Studies ,Tomography ,X-Ray Computed ,computed tomography ,deep learning ,idiopathic pulmonary fibrosis ,optimal design ,Other Physical Sciences ,Oncology and Carcinogenesis ,Nuclear Medicine & Medical Imaging ,Biomedical engineering ,Medical and biological physics - Abstract
PurposeDomain knowledge (DK) acquired from prior studies is important for medical diagnosis. This paper leverages the population-level DK using an optimality design criterion to train a deep learning model in an end-to-end manner. In this study, the problem of interest is at the patient level to diagnose a subject with idiopathic pulmonary fibrosis (IPF) among subjects with interstitial lung disease (ILD) using a computed tomography (CT). IPF diagnosis is a complicated process with multidisciplinary discussion with experts and is subject to interobserver variability, even for experienced radiologists. To this end, we propose a new statistical method to construct a time/memory-efficient IPF diagnosis model using axial chest CT and DK, along with an optimality design criterion via a DK-enhanced loss function of deep learning.MethodsFour state-of-the-art two-dimensional convolutional neural network (2D-CNN) architectures (MobileNet, VGG16, ResNet-50, and DenseNet-121) and one baseline 2D-CNN are implemented to automatically diagnose IPF among ILD patients. Axial lung CT images are retrospectively acquired from 389 IPF patients and 700 non-IPF ILD patients in five multicenter clinical trials. To enrich the sample size and boost model performance, we sample 20 three-slice samples (triplets) from each CT scan, where these three slices are randomly selected from the top, middle, and bottom of both lungs respectively. Model performance is evaluated using a fivefold cross-validation, where each fold was stratified using a fixed proportion of IPF vs non-IPF.ResultsUsing DK-enhanced loss function increases the model performance of the baseline CNN model from 0.77 to 0.89 in terms of study-wise accuracy. Four other well-developed models reach satisfactory model performance with an overall accuracy >0.95 but the benefits brought on by the DK-enhanced loss function is not noticeable.ConclusionsWe believe this is the first attempt that (a) uses population-level DK with an optimal design criterion to train deep learning-based diagnostic models in an end-to-end manner and (b) focuses on patient-level IPF diagnosis. Further evaluation of using population-level DK on prospective studies is warranted and is underway.
- Published
- 2021
9. Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials
- Author
-
Ellingson, Benjamin M, Brown, Matthew S, Boxerman, Jerrold L, Gerstner, Elizabeth R, Kaufmann, Timothy J, Cole, Patricia E, Bacha, Jeffrey A, Leung, David, Barone, Amy, Colman, Howard, van den Bent, Martin J, Wen, Patrick Y, Yung, WK Alfred, Cloughesy, Timothy F, and Goldin, Jonathan G
- Subjects
Clinical Trials and Supportive Activities ,Cancer ,Biomedical Imaging ,Brain Disorders ,Clinical Research ,Brain Neoplasms ,Diagnostic Imaging ,Humans ,Laboratories ,clinical trials ,Imaging Charter ,imaging endpoints ,neuro-oncology ,RANO ,Neurosciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Determination of therapeutic benefit in intracranial tumors is intimately dependent on serial assessment of radiographic images. The Response Assessment in Neuro-Oncology (RANO) criteria were established in 2010 to provide an updated framework to better characterize tumor response to contemporary treatments. Since this initial update a number of RANO criteria have provided some basic principles for the interpretation of changes on MR images; however, the details of how to operationalize RANO and other criteria for use in clinical trials are ambiguous and not standardized. In this review article designed for the neuro-oncologist or treating clinician, we outline essential steps for performing radiographic assessments by highlighting primary features of the Imaging Charter (referred to as the Charter for the remainder of this article), a document that describes the clinical trial imaging methodology and methods to ensure operationalization of the Charter into the workings of a clinical trial. Lastly, we provide recommendations for specific changes to optimize this methodology for neuro-oncology, including image registration, requirement of growing tumor for eligibility in trials of recurrent tumor, standardized image acquisition guidelines, and hybrid reader paradigms that allow for both unbiased measurements and more comprehensive interpretation.
- Published
- 2021
10. Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.
- Author
-
Kim, Grace Hyun J, Tashkin, Donald P, Lo, Pechin, Brown, Matthew S, Volkmann, Elizabeth R, Gjertson, David W, Khanna, Dinesh, Elashoff, Robert M, Tseng, Chi-Hong, Roth, Michael D, and Goldin, Jonathan G
- Subjects
Humans ,Lung Diseases ,Interstitial ,Scleroderma ,Systemic ,Mycophenolic Acid ,Cyclophosphamide ,Immunosuppressive Agents ,Tomography ,X-Ray Computed ,Treatment Outcome ,Adult ,Middle Aged ,Female ,Male ,Rare Diseases ,Clinical Research ,Scleroderma ,Biomedical Imaging ,Autoimmune Disease ,Lung ,Respiratory ,Clinical Sciences ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology - Abstract
ObjectiveTo examine changes in the extent of specific patterns of interstitial lung disease (ILD) as they transition from one pattern to another in response to immunosuppressive therapy in systemic sclerosis-related ILD (SSc-ILD).MethodsWe evaluated changes in the quantitative extent of specific lung patterns of ILD using volumetric high-resolution computed tomography (HRCT) scans obtained at baseline and after 2 years of therapy in patients treated with either cyclophosphamide (CYC) for 1 year or mycophenolate mofetil (MMF) for 2 years in Scleroderma Lung Study II. ILD patterns included lung fibrosis, ground glass, honeycombing, and normal lung. Net change was calculated as the difference in the probability of change from one ILD pattern to another. Wilcoxon's signed rank test was used to compare the changes.ResultsForty-seven and 50 patients had baseline and follow-up scans in the CYC and MMF groups, respectively. Mean net improvements reflecting favorable changes from one ILD pattern to another in the whole lung in the CYC and MMF groups, respectively, were as follows: from lung fibrosis to a normal lung pattern, 21% and 19%; from a ground-glass pattern to a normal lung pattern, 30% and 28%; and from lung fibrosis to a ground-glass pattern, 5% and 0.5%. The mean overall improvement in transitioning from a ground-glass pattern or lung fibrosis to a normal lung pattern was significant for both treatments (all P < 0.001).ConclusionSignificantly favorable transitions from both ground-glass and lung fibrosis ILD patterns to a normal lung pattern were observed in patients undergoing immunosuppressive treatment for SSc-ILD, suggesting the usefulness of examining these transitions for insights into the underlying pathobiology of treatment response.
- Published
- 2020
11. Automated Endotracheal Tube Placement Check Using Semantically Embedded Deep Neural Networks
- Author
-
Brown, Matthew S., Wong, Koon-Pong, Shrestha, Liza, Wahi-Anwar, Muhammad, Daly, Morgan, Foster, George, Abtin, Fereidoun, Ruchalski, Kathleen L., Goldin, Jonathan G., and Enzmann, Dieter
- Published
- 2023
- Full Text
- View/download PDF
12. Quantifying lung fissure integrity using a three-dimensional patch-based convolutional neural network on CT images for emphysema treatment planning
- Author
-
Tada, Dallas K., primary, Teng, Pangyu, additional, Vyapari, Kalyani, additional, Banola, Ashley, additional, Foster, George, additional, Diaz, Esteban, additional, Kim, Grace Hyun J., additional, Goldin, Jonathan G., additional, Abtin, Fereidoun, additional, McNitt-Gray, Michael, additional, and Brown, Matthew S., additional
- Published
- 2024
- Full Text
- View/download PDF
13. Prediction of progression in idiopathic pulmonary fibrosis using CT scans atbaseline: A quantum particle swarm optimization - Random forest approach
- Author
-
Shi, Yu, Wong, Weng Kee, Goldin, Jonathan G., Brown, Matthew S., and Kim, Grace Hyun J.
- Subjects
Biomedical imaging ,Texture features ,Wrapper methods - Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by an unpredictable progressive declinein lung function. Natural history of IPF is unknown and the prediction of disease progression at the time ofdiagnosis is notoriously difficult. High resolution computed tomography (HRCT) has been used for the diagnosisof IPF, but not generally for monitoring purpose. The objective of this work is to develop a novel predictivemodel for the radiological progression pattern at voxel-wise level using only baseline HRCT scans. Mainly, thereare two challenges: (a) obtaining a data set of features for region of interest (ROI) on baseline HRCT scans andtheir follow-up status; and (b) simultaneously selecting important features from high-dimensional space, andoptimizing the prediction performance. We resolved the first challenge by implementing a study design andhaving an expert radiologist contour ROIs at baseline scans, depending on its progression status in follow-upvisits. For the second challenge, we integrated the feature selection with prediction by developing an algorithmusing a wrapper method that combines quantum particle swarm optimization to select a small number of featureswith random forest to classify early patterns of progression. We applied our proposed algorithm to analyzeanonymized HRCT images from 50 IPF subjects from a multi-center clinical trial. We showed that it yields aparsimonious model with 81.8% sensitivity, 82.2% specificity and an overall accuracy rate of 82.1% at the ROIlevel. These results are superior to other popular feature selections and classification methods, in that ourmethod produces higher accuracy in prediction of progression and more balanced sensitivity and specificity witha smaller number of selected features. Our work is the first approach to show that it is possible to use onlybaseline HRCT scans to predict progressive ROIs at 6 months to 1year follow-ups using artificial intelligence.
- Published
- 2019
14. Longitudinal Changes in Quantitative Interstitial Lung Disease on CT after Immunosuppression in the Scleroderma Lung Study II
- Author
-
Goldin, Jonathan G, Kim, Grace Hyun J, Tseng, Chi-Hong, Volkmann, Elizabeth, Furst, Daniel, Clements, Philip, Brown, Matt, Roth, Michael, Khanna, Dinesh, and Tashkin, Donald P
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Clinical Research ,Clinical Trials and Supportive Activities ,Scleroderma ,Biomedical Imaging ,Rare Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Respiratory ,Adult ,Cyclophosphamide ,Double-Blind Method ,Female ,Humans ,Immunosuppression Therapy ,Immunosuppressive Agents ,Longitudinal Studies ,Lung Diseases ,Interstitial ,Male ,Middle Aged ,Mycophenolic Acid ,Scleroderma ,Systemic ,Tomography ,X-Ray Computed ,Scleroderma Lung Study II ,mycophenolate mofetil ,cyclophosphamide ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
RationaleThe Scleroderma Lung Study II (SLS II) demonstrated significant improvements in pulmonary function and dyspnea at 24 months compared with baseline when patients with symptomatic scleroderma-related interstitial lung disease (SSc-ILD) were treated with either cyclophosphamide for 1 year (followed for another year on placebo) or mycophenolate mofetil for 2 years in a randomized, double-blind clinical trial. Physiologic and clinical outcomes of SLS II have been published previously.ObjectivesThe aim of the study was to assess changes from baseline in the extent of SSc-ILD on high-resolution computed tomography (HRCT) measured in the SLS II participants using quantitative image analysis after 2 years and to determine whether these HRCT changes were correlated with the changes in physiologic and clinical measures over the same time interval.MethodsNinety-seven of the 142 randomized subjects (cyclophosphamide group, 47 subjects; mycophenolate mofetil group, 50 subjects) participating in SLS II underwent thoracic volumetric thin-section HRCT at both baseline and 24 months. Quantitative computer-aided diagnosis scores using volumetric HRCT scans were obtained using a previously developed computer-aided system. The scores were quantitative lung fibrosis, quantitative ground glass, quantitative honeycomb, and quantitative interstitial lung disease (QILD), the latter representing the sum of quantitative lung fibrosis, quantitative ground glass, and quantitative honeycomb. These scores were obtained both for the whole lung and for individual lobes. Paired t tests were used for the combined (pooled) cyclophosphamide and mycophenolate mofetil groups to compare 24-month changes from baseline in both the whole lung and the lobe of maximal involvement as determined at baseline (worst lobe).ResultsAt the end of the 24-month trial, QILD in the whole lung was significantly reduced by a mean of 2.51% in the pooled groups (adjusted 95% confidence interval, -4.00 to -1.03%; P = 0.001). There was no significant difference in the QILD score improvement between the cyclophosphamide (-2.66%) and mycophenolate (-2.38%) groups when assessed separately (P = 0.88). For the pooled group, the 24-month changes in QILD scores in the whole lung correlated significantly with other outcomes, including 24-month changes in forced vital capacity (ρ = -0.37), single-breath diffusing capacity of the lung for carbon monoxide (ρ = -0.22), and breathlessness as measured by the Transition Dyspnea Index (ρ = -0.26).ConclusionsTreatment of SSc-ILD with either cyclophosphamide for 1 year, followed by placebo for a second year, or mycophenolate for 2 years was associated with a significant reduction (improvement) in the extent of HRCT SSc-ILD assessed by computer-aided diagnosis scores, which correlated well with one or more other measures of treatment response. These findings demonstrate that actual changes in lung structure accompany improvements in physiologic and/or symptomatic measures in SSc-ILD.
- Published
- 2018
15. Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative
- Author
-
Abtin, Fereidoun, Antoniou, Katerina, Blackwell, Timothy, Brown, Kevin, Chung, Jonathan, Corte, Tamera, Crestani, Bruno, Crossno, Peter, Culver, Daniel, de Andrade, Joao, Deveraj, Anand, Flaherty, Kevin, Gudmundsson, Gunnar, Hatabu, Hiroto, Jacob, Joe, Johansson, Kerri, Kanne, Jeff, Kazerooni, Ella, Kolb, Martin, Lynch, David, Maher, Toby, Martinez, Fernando, Morais, Antonio, Nathan, Steven D., Noth, Imre, Oldham, Justin, Podolanczuk, Anna, Poletti, Venerino, Ravaglia, Claudia, Renzoni, Elizabetta, Richeldi, Luca, Rubin, Geoffrey, Ryerson, Chris, Sahoo, Debasis, Tomassetti, Sara, Spagnolo, Paolo, Strek, Mary E., Suh, Rob, Sverzellati, Nicola, Valeyre, Dominique, Walsh, Simon, Washko, George, White, Eric S., Hunninghake, Gary M., Goldin, Jonathan G., Kadoch, Michael A., Kropski, Jonathan A., Rosas, Ivan O., Wells, Athol U., Yadav, Ruchi, Lazarus, Howard M., Abtin, Fereidoun G., Corte, Tamera J., de Andrade, Joao A., Johannson, Kerri A., Kolb, Martin R., Lynch, David A., Oldham, Justin M., and Washko, George R.
- Published
- 2022
- Full Text
- View/download PDF
16. Interpretation of HRCT Scans in the Diagnosis of IPF: Improving Communication Between Pulmonologists and Radiologists
- Author
-
Chung, Jonathan H and Goldin, Jonathan G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Autoimmune Disease ,Rare Diseases ,Lung ,Biomedical Imaging ,7.3 Management and decision making ,4.2 Evaluation of markers and technologies ,Management of diseases and conditions ,Detection ,screening and diagnosis ,Respiratory ,Aged ,Female ,Humans ,Idiopathic Pulmonary Fibrosis ,Interdisciplinary Communication ,Male ,Medical History Taking ,Middle Aged ,Pathologists ,Pulmonologists ,Radiologists ,Rheumatologists ,Serologic Tests ,Tomography ,X-Ray Computed ,Interstitial lung disease ,Idiopathic pulmonary fibrosis ,Diagnostic criteria ,Multidisciplinary discussion ,High-resolution computed tomography ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease (ILD). In this review, we describe the central role of high-resolution computed tomography (HRCT) in the diagnosis of IPF and discuss how communication between pulmonologists and radiologists might be improved to make the interpretation of HRCT scans more effective. Clinical information is important in the interpretation of HRCT scans, as the likelihood that specific radiologic features reflect IPF is not absolute, but dependent on the clinical context. In cases where the clinical context or HRCT pattern are inconclusive, multidisciplinary discussion (MDD) between a pulmonologist and radiologist (and, where relevant, a pathologist and rheumatologist) experienced in the differential diagnosis of ILD is necessary to establish a diagnosis. While it can be challenging to convene a face-to-face meeting, MDD can be conducted virtually or by telephone to enable each specialty group to contribute. To make the MDD most effective, it is important that relevant clinical information (for example, on the patient's clinical history, exposures and the results of serological tests) is shared with all parties in advance. A common lexicon to describe HRCT features observed in ILD can also help improve the effectiveness of MDD. A working diagnosis may be made in patients who do not fulfill all the diagnostic criteria for any specific type of ILD, but this diagnosis should be reviewed at regular intervals, with repeat of clinical, radiological, and laboratory assessments as appropriate, as new information pertinent to the patient's diagnosis may become available.
- Published
- 2018
17. Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate
- Author
-
Nagarajan, Mahesh B, Raman, Steven S, Lo, Pechin, Lin, Wei-Chan, Khoshnoodi, Pooria, Sayre, James W, Ramakrishna, Bharath, Ahuja, Preeti, Huang, Jiaoti, Margolis, Daniel JA, Lu, David SK, Reiter, Robert E, Goldin, Jonathan G, Brown, Matthew S, and Enzmann, Dieter R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Prostate Cancer ,Urologic Diseases ,Biomedical Imaging ,Clinical Research ,Cancer ,Adult ,Aged ,Algorithms ,Biopsy ,Humans ,Image Interpretation ,Computer-Assisted ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neoplasm Grading ,Probability ,Prostatectomy ,Prostatic Neoplasms ,Retrospective Studies ,Prostate cancer ,Multi-parametric ,MRI ,Tumor occurrence probability map ,Prostate registration ,Multi-parametric MRI - Abstract
PurposeWe present a method for generating a T2 MR-based probabilistic model of tumor occurrence in the prostate to guide the selection of anatomical sites for targeted biopsies and serve as a diagnostic tool to aid radiological evaluation of prostate cancer.Materials and methodsIn our study, the prostate and any radiological findings within were segmented retrospectively on 3D T2-weighted MR images of 266 subjects who underwent radical prostatectomy. Subsequent histopathological analysis determined both the ground truth and the Gleason grade of the tumors. A randomly chosen subset of 19 subjects was used to generate a multi-subject-derived prostate template. Subsequently, a cascading registration algorithm involving both affine and non-rigid B-spline transforms was used to register the prostate of every subject to the template. Corresponding transformation of radiological findings yielded a population-based probabilistic model of tumor occurrence. The quality of our probabilistic model building approach was statistically evaluated by measuring the proportion of correct placements of tumors in the prostate template, i.e., the number of tumors that maintained their anatomical location within the prostate after their transformation into the prostate template space.ResultsProbabilistic model built with tumors deemed clinically significant demonstrated a heterogeneous distribution of tumors, with higher likelihood of tumor occurrence at the mid-gland anterior transition zone and the base-to-mid-gland posterior peripheral zones. Of 250 MR lesions analyzed, 248 maintained their original anatomical location with respect to the prostate zones after transformation to the prostate.ConclusionWe present a robust method for generating a probabilistic model of tumor occurrence in the prostate that could aid clinical decision making, such as selection of anatomical sites for MR-guided prostate biopsies.
- Published
- 2018
18. Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer
- Author
-
Brown, Matthew S, Kim, Grace Hyun J, Chu, Gregory H, Ramakrishna, Bharath, Allen-Auerbach, Martin, Fischer, Cheryce P, Levine, Benjamin, Gupta, Pawan K, Schiepers, Christiaan W, and Goldin, Jonathan G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Clinical Research ,Prostate Cancer ,Urologic Diseases ,Cancer ,Clinical Trials and Supportive Activities ,4.1 Discovery and preclinical testing of markers and technologies ,Evaluation of treatments and therapeutic interventions ,Detection ,screening and diagnosis ,6.1 Pharmaceuticals ,prostate cancer ,bone scan ,computer-aided diagnosis ,Clinical sciences ,Biomedical engineering - Abstract
A clinical validation of the bone scan lesion area (BSLA) as a quantitative imaging biomarker was performed in metastatic castration-resistant prostate cancer (mCRPC). BSLA was computed from whole-body bone scintigraphy at baseline and week 12 posttreatment in a cohort of 198 mCRPC subjects (127 treated and 71 placebo) from a clinical trial involving a different drug from the initial biomarker development. BSLA computation involved automated image normalization, lesion segmentation, and summation of the total area of segmented lesions on bone scan AP and PA views as a measure of tumor burden. As a predictive biomarker, treated subjects with baseline BSLA [Formula: see text] had longer survival than those with higher BSLA ([Formula: see text] and [Formula: see text]). As a surrogate outcome biomarker, subjects were categorized as progressive disease (PD) if the BSLA increased by a prespecified 30% or more from baseline to week 12 and non-PD otherwise. Overall survival rates between PD and non-PD groups were statistically different ([Formula: see text] and [Formula: see text]). Subjects without PD at week 12 had longer survival than subjects with PD: median 398 days versus 280 days. BSLA has now been demonstrated to be an early surrogate outcome for overall survival in different prostate cancer drug treatments.
- Published
- 2018
19. Quantitative Computed Tomography Lung COVID Scores with Laboratory Markers: Utilization to Predict Rapid Progression and Monitor Longitudinal Changes in Patients with Coronavirus 2019 (COVID-19) Pneumonia
- Author
-
Kang, Da Hyun, primary, Kim, Grace Hyun J., additional, Park, Sa-Beom, additional, Lee, Song-I, additional, Koh, Jeong Suk, additional, Brown, Matthew S., additional, Abtin, Fereidoun, additional, McNitt-Gray, Michael F., additional, Goldin, Jonathan G., additional, and Lee, Jeong Seok, additional
- Published
- 2024
- Full Text
- View/download PDF
20. Robustness-Driven Feature Selection in Classification of Fibrotic Interstitial Lung Disease Patterns in Computed Tomography Using 3D Texture Features
- Author
-
Chong, Daniel Y, Kim, Hyun J, Lo, Pechin, Young, Stefano, McNitt-Gray, Michael F, Abtin, Fereidoun, Goldin, Jonathan G, and Brown, Matthew S
- Subjects
Information and Computing Sciences ,Clinical Research ,Lung ,Biomedical Imaging ,Bioengineering ,Respiratory ,Humans ,Image Processing ,Computer-Assisted ,Lung Diseases ,Interstitial ,Machine Learning ,Pattern Recognition ,Automated ,Pulmonary Fibrosis ,Tomography ,X-Ray Computed ,High-resolution computed tomography ,machine learning ,pattern recognition and classification ,fibrotic interstitial lung disease ,Engineering ,Nuclear Medicine & Medical Imaging ,Information and computing sciences - Abstract
Lack of classifier robustness is a barrier to widespread adoption of computer-aided diagnosis systems for computed tomography (CT). We propose a novel Robustness-Driven Feature Selection (RDFS) algorithm that preferentially selects features robust to variations in CT technical factors. We evaluated RDFS in CT classification of fibrotic interstitial lung disease using 3D texture features. CTs were collected for 99 adult subjects separated into three datasets: training, multi-reconstruction, testing. Two thoracic radiologists provided cubic volumes of interest corresponding to six classes: pulmonary fibrosis, ground-glass opacity, honeycombing, normal lung parenchyma, airway, vessel. The multi-reconstruction dataset consisted of CT raw sinogram data reconstructed by systematically varying slice thickness, reconstruction kernel, and tube current (using a synthetic reduced-tube-current algorithm). Two support vector machine classifiers were created, one using RDFS ("with-RDFS") and one not ("without-RDFS"). Classifier robustness was compared on the multi-reconstruction dataset, using Cohen's kappa to assess classification agreement against a reference reconstruction. Classifier performance was compared on the testing dataset using the extended g-mean (EGM) measure. With-RDFS exhibited superior robustness (kappa 0.899-0.989) compared to without-RDFS (kappa 0.827-0.968). Both classifiers demonstrated similar performance on the testing dataset (EGM 0.778 for with-RDFS; 0.785 for without-RDFS), indicating that RDFS does not compromise classifier performance when discarding nonrobust features. RDFS is highly effective at improving classifier robustness against slice thickness, reconstruction kernel, and tube current without sacrificing performance, a result that has implications for multicenter clinical trials that rely on accurate and reproducible quantitative analysis of CT images collected under varied conditions across multiple sites, scanners, and timepoints.
- Published
- 2016
21. Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18–24-month follow-ups
- Author
-
Kim, Grace Hyun J., Weigt, Stephan S., Belperio, John A., Brown, Matthew S., Shi, Yu, Lai, Joshua H., and Goldin, Jonathan G.
- Published
- 2020
- Full Text
- View/download PDF
22. Toward clinically usable CAD for lung cancer screening with computed tomography.
- Author
-
Brown, Matthew S, Lo, Pechin, Goldin, Jonathan G, Barnoy, Eran, Kim, Grace Hyun J, McNitt-Gray, Michael F, and Aberle, Denise R
- Subjects
Lung ,Humans ,Lung Neoplasms ,Diagnosis ,Differential ,Tomography ,X-Ray Computed ,Reproducibility of Results ,ROC Curve ,Female ,Male ,Early Detection of Cancer ,Lung Cancer ,Clinical Trials and Supportive Activities ,Bioengineering ,Cancer ,Clinical Research ,Biomedical Imaging ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Lung cancer ,Multiple pulmonary nodules ,Computer-assisted diagnosis ,Early detection of cancer ,X-ray computerized axial tomography ,Clinical Sciences ,Nuclear Medicine & Medical Imaging - Abstract
ObjectivesThe purpose of this study was to define clinically appropriate, computer-aided lung nodule detection (CAD) requirements and protocols based on recent screening trials. In the following paper, we describe a CAD evaluation methodology based on a publically available, annotated computed tomography (CT) image data set, and demonstrate the evaluation of a new CAD system with the functionality and performance required for adoption in clinical practice.MethodsA new automated lung nodule detection and measurement system was developed that incorporates intensity thresholding, a Euclidean Distance Transformation, and segmentation based on watersheds. System performance was evaluated against the Lung Imaging Database Consortium (LIDC) CT reference data set.ResultsThe test set comprised thin-section CT scans from 108 LIDC subjects. The median (±IQR) sensitivity per subject was 100 (±37.5) for nodules ≥ 4 mm and 100 (±8.33) for nodules ≥ 8 mm. The corresponding false positive rates were 0 (±2.0) and 0 (±1.0), respectively. The concordance correlation coefficient between the CAD nodule diameter and the LIDC reference was 0.91, and for volume it was 0.90.ConclusionsThe new CAD system shows high nodule sensitivity with a low false positive rate. Automated volume measurements have strong agreement with the reference standard. Thus, it provides comprehensive, clinically-usable lung nodule detection and assessment functionality.Key points• CAD requirements can be based on lung cancer screening trial results. • CAD systems can be evaluated using publically available annotated CT image databases. • A new CAD system was developed with a low false positive rate. • The CAD system has reliable measurement tools needed for clinical use.
- Published
- 2014
23. Prediction of progression in idiopathic pulmonary fibrosis using CT scans at baseline: A quantum particle swarm optimization - Random forest approach
- Author
-
Shi, Yu, Wong, Weng Kee, Goldin, Jonathan G., Brown, Matthew S., and Kim, Grace Hyun J.
- Published
- 2019
- Full Text
- View/download PDF
24. COMPUTER-ASSISTED QUANTITATIVE IMAGE ANALYSIS FOR IDENTIFICATION OF PULMONARY FIBROSIS AND EMPHYSEMA: PATHWAY TO CHARACTERIZING CPFE
- Author
-
HOESTEREY, DANIEL, primary, HYUN KIM, GRACE, additional, LEE, JIHEY, additional, OH, ANDREA, additional, POURZAND, LILA, additional, GOLDIN, JONATHAN G, additional, HOFFMAN, ERIC A, additional, WANG, JENNIFER, additional, HAN, MEILAN K, additional, COOPER, CHRISTOPHER B, additional, TASHKIN, DONALD P, additional, BARJAKTAREVIC, IGOR, additional, and ABTIN, FEREIDOUN, additional
- Published
- 2023
- Full Text
- View/download PDF
25. ASSOCIATION OF HRCT PATTERNS AND TRANSPLANT-FREE SURVIVAL IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS) IN THE ILD-PRO REGISTRY
- Author
-
SWAMINATHAN, APARNA, primary, M WHELAN, TIMOTHY P, additional, NEELY, MEGAN L, additional, TODD, JAMIE, additional, PALMER, SCOTT M, additional, WOJDYLA, DANIEL, additional, HYUN KIM, GRACE, additional, LI, PEIDE, additional, LEONARD, THOMAS, additional, CONOSCENTI, CRAIG S, additional, and GOLDIN, JONATHAN G, additional
- Published
- 2023
- Full Text
- View/download PDF
26. Late Breaking Abstract - Safety, tolerability and antifibrotic activity of bexotegrast: Phase 2a INTEGRIS-IPF study (NCT04396756)
- Author
-
Wuyts, Wim A, primary, Valenzuela, Claudia, additional, Jenkins, Gisli, additional, Goldin, Jonathan G, additional, Kim, Grace Hyun J, additional, Jurek, Marzena, additional, Turner, Scott, additional, Decaris, Martin, additional, Barnes, Chris N, additional, Lefebvre, Éric, additional, Cosgrove, Gregory, additional, and Cottin, Vincent, additional
- Published
- 2023
- Full Text
- View/download PDF
27. Radiologist and Radiology Practice Wellbeing: A Report of the 2023 ARRS Wellness Summit
- Author
-
Azour, Lea, primary, Goldin, Jonathan G., additional, and Kruskal, Jonathan B., additional
- Published
- 2023
- Full Text
- View/download PDF
28. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
- Author
-
Lynch, David A, Sverzellati, Nicola, Travis, William D, Brown, Kevin K, Colby, Thomas V, Galvin, Jeffrey R, Goldin, Jonathan G, Hansell, David M, Inoue, Yoshikazu, Johkoh, Takeshi, Nicholson, Andrew G, Knight, Shandra L, Raoof, Suhail, Richeldi, Luca, Ryerson, Christopher J, Ryu, Jay H, and Wells, Athol U
- Published
- 2018
- Full Text
- View/download PDF
29. A method for the automatic quantification of the completeness of pulmonary fissures: evaluation in a database of subjects with severe emphysema
- Author
-
van Rikxoort, Eva M, Goldin, Jonathan G, Galperin-Aizenberg, Maya, Abtin, Fereidoun, Kim, Hyun J, Lu, Peiyun, van Ginneken, Bram, Shaw, Greg, and Brown, Matthew S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Biomedical Imaging ,Emphysema ,Chronic Obstructive Pulmonary Disease ,Algorithms ,Automation ,Body Mass Index ,Electronic Data Processing ,Female ,Humans ,Image Processing ,Computer-Assisted ,Male ,Observer Variation ,Pattern Recognition ,Automated ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,ROC Curve ,Software ,Tomography ,X-Ray Computed ,Lung/radiography ,X-ray computed tomography ,Computer-assisted radiographic image interpretation ,Chronic obstructive pulmonary disease ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
ObjectivesTo propose and evaluate a technique for automatic quantification of fissural completeness from chest computed tomography (CT) in a database of subjects with severe emphysema.MethodsNinety-six CT studies of patients with severe emphysema were included. The lungs, fissures and lobes were automatically segmented. The completeness of the fissures was calculated as the percentage of the lobar border defined by a fissure. The completeness score of the automatic method was compared with a visual consensus read by three radiologists using boxplots, rank sum tests and ROC analysis.ResultsThe consensus read found 49% (47/96), 15% (14/96) and 67% (64/96) of the right major, right minor and left major fissures to be complete. For all fissures visually assessed as being complete the automatic method resulted in significantly higher completeness scores (mean 92.78%) than for those assessed as being partial or absent (mean 77.16%; all p values
- Published
- 2012
30. Eosinophil and T cell markers predict functional decline in COPD patients
- Author
-
D'Armiento, Jeanine M, Scharf, Steven M, Roth, Michael D, Connett, John E, Ghio, Andrew, Sternberg, David, Goldin, Jonathan G, Louis, Thomas A, Mao, Jenny T, O'Connor, George T, Ramsdell, Joe W, Ries, Andrew L, Schluger, Neil W, Sciurba, Frank C, Skeans, Melissa A, Voelker, Helen, Walter, Robert E, Wendt, Christine H, Weinmann, Gail G, Wise, Robert A, and Foronjy, Robert F
- Abstract
Abstract Background The major marker utilized to monitor COPD patients is forced expiratory volume in one second (FEV1). However, asingle measurement of FEV1 cannot reliably predict subsequent decline. Recent studies indicate that T lymphocytes and eosinophils are important determinants of disease stability in COPD. We therefore measured cytokine levels in the lung lavage fluid and plasma of COPD patients in order to determine if the levels of T cell or eosinophil related cytokines were predictive of the future course of the disease. Methods Baseline lung lavage and plasma samples were collected from COPD subjects with moderately severe airway obstruction and emphysematous changes on chest CT. The study participants were former smokers who had not had a disease exacerbation within the past six months or used steroids within the past two months. Those subjects who demonstrated stable disease over the following six months (ΔFEV1 % predicted = 4.7 ± 7.2; N = 34) were retrospectively compared with study participants who experienced a rapid decline in lung function (ΔFEV1 % predicted = -16.0 ± 6.0; N = 16) during the same time period and with normal controls (N = 11). Plasma and lung lavage cytokines were measured from clinical samples using the Luminex multiplex kit which enabled the simultaneous measurement of several T cell and eosinophil related cytokines. Results and Discussion Stable COPD participants had significantly higher plasma IL-2 levels compared to participants with rapidly progressive COPD (p = 0.04). In contrast, plasma eotaxin-1 levels were significantly lower in stable COPD subjects compared to normal controls (p < 0.03). In addition, lung lavage eotaxin-1 levels were significantly higher in rapidly progressive COPD participants compared to both normal controls (p < 0.02) and stable COPD participants (p < 0.05). Conclusion These findings indicate that IL-2 and eotaxin-1 levels may be important markers of disease stability in advanced emphysema patients. Prospective studies will need to confirm whether measuring IL-2 or eotaxin-1 can identify patients at risk for rapid disease progression.
- Published
- 2009
31. Radiofrequency Ablation of Subpleural Lung Malignancy: Reduced Pain Using an Artificially Created Pneumothorax
- Author
-
Lee, Edward W., Suh, Robert D., Zeidler, Michelle R., Tsai, Irene S., Cameron, Robert B., Abtin, Fereidoun G., and Goldin, Jonathan G.
- Subjects
Medicine & Public Health ,Cardiology ,Ultrasound ,Nuclear Medicine ,Imaging / Radiology ,Radiofrequency ablation ,Subpleural lung malignancy ,Iatrogenic pneumothorax - Abstract
One of the main issues with radiofrequency (RF) ablation of the subpleural lung malignancy is pain management during and after RF ablation. In this article, we present a case that utilized a technique to decrease the pain associated with RF ablation of a malignancy located within the subpleural lung. Under CT guidance, we created an artificial pneumothorax prior to the RF ablation, which resulted in minimizing the pain usually experienced during and after the procedure. It also decreased the amount of pain medications usually used in patients undergoing RF ablation of a subpleural lung lesion.
- Published
- 2009
32. Lung Cancer Screening Among Mammography Patients: Knowledge, Eligibility, Participation, and Interest
- Author
-
Novogrodsky, Eitan, primary, Haramati, Linda B., additional, Villasana-Gomez, Geraldine M., additional, Goldman, Jessica, additional, Rosenfeld, Cyril, additional, Rosenblum, Jessica K., additional, Sayre, James W., additional, Hoyt, Anne C., additional, Goldin, Jonathan G., additional, and Milch, Hannah S., additional
- Published
- 2023
- Full Text
- View/download PDF
33. Translating AI to Clinical Practice: Overcoming Data Shift with Explainability
- Author
-
Choi, Youngwon, primary, Yu, Wenxi, additional, Nagarajan, Mahesh B., additional, Teng, Pangyu, additional, Goldin, Jonathan G., additional, Raman, Steven S., additional, Enzmann, Dieter R., additional, Kim, Grace Hyun J., additional, and Brown, Matthew S., additional
- Published
- 2023
- Full Text
- View/download PDF
34. Predicting endobronchial valve treatment response in emphysema patients using the lung fissure integrity score extracted from chest CT scans
- Author
-
Chen, Weijie, Astley, Susan M., Tada, Dallas K., Kim, Grace H., Teng, Pangyu, Vyapari, Kalyani, Banola, Ashley, Abtin, Fereidoun, Goldin, Jonathan G., McNitt-Gray, Michael, and Brown, Matthew S.
- Published
- 2024
- Full Text
- View/download PDF
35. Quantitative interstitial lung disease scores in idiopathic inflammatory myopathies: longitudinal changes and clinical implications.
- Author
-
Yeo, Jina, Yoon, Soon Ho, Kim, Ju Yeon, Lee, Jeong Seok, Lee, Eun Young, Goo, Jin Mo, Pourzand, Lila, Goldin, Jonathan G, Kim, Grace‐Hyun J, and Ha, You‐Jung
- Subjects
BIOMARKERS ,DISEASE progression ,MUSCLE diseases ,INFLAMMATION ,LUNG transplantation ,MULTIVARIATE analysis ,INTERSTITIAL lung diseases ,QUANTITATIVE research ,RETROSPECTIVE studies ,VITAL capacity (Respiration) ,DESCRIPTIVE statistics ,RESEARCH funding ,MYOSITIS ,COMPUTER-aided diagnosis ,COMPUTED tomography ,LOGISTIC regression analysis ,DATA analysis software ,PROGRESSION-free survival ,LONGITUDINAL method ,DISEASE complications - Abstract
Objectives To investigate computer-aided quantitative scores from high‐resolution CT (HRCT) images and determine their longitudinal changes and clinical significance in patients with idiopathic inflammatory myopathies (IIMs)-related interstitial lung disease (IIMs-ILD). Methods The clinical data and HRCT images of 80 patients with IIMs who underwent serial HRCT scans at least twice were retrospectively analysed. Quantitative ILD (QILD) scores (%) were calculated as the sum of the extent of lung fibrosis, ground-glass opacity, and honeycombing. The individual time-estimated ΔQILD between two consecutive scans was derived using a linear approximation of yearly changes. Results The baseline median QILD (interquartile range) scores in the whole lung were 28.1% (19.1–43.8). The QILD was significantly correlated with forced vital capacity (r = −0.349, P = 0.002) and diffusing capacity for carbon monoxide (r = −0.381, P = 0.001). For ΔQILD between the first two scans, according to the visual ILD subtype, QILD aggravation was more frequent in patients with usual interstitial pneumonia (UIP) than non-UIP (80.0% vs 44.4%, P = 0.013). Multivariable logistic regression analyses identified UIP was significantly related to radiographic ILD progression (ΔQILD >2%, P = 0.015). Patients with higher baseline QILD scores (>28.1%) had a higher risk of lung transplantation or death (P = 0.015). In the analysis of three serial HRCT scans (n = 41), dynamic ΔQILD with four distinct patterns (improving, worsening, convex and concave) was observed. Conclusion QILD changes in IIMs-ILD were dynamic, and baseline UIP patterns seemed to be related to a longitudinal progression in QILD. These may be potential imaging biomarkers for lung function, changes in ILD severity and prognosis in IIMs-ILD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Quantitative Imaging Metrics for the Assessment of Pulmonary Pathophysiology: An Official American Thoracic Society and Fleischner Society Joint Workshop Report
- Author
-
Hsia, Connie C. W., primary, Bates, Jason H. T., additional, Driehuys, Bastiaan, additional, Fain, Sean B., additional, Goldin, Jonathan G., additional, Hoffman, Eric A., additional, Hogg, James C., additional, Levin, David L., additional, Lynch, David A., additional, Ochs, Matthias, additional, Parraga, Grace, additional, Prisk, G. Kim, additional, Smith, Benjamin M., additional, Tawhai, Merryn, additional, Vidal Melo, Marcos F., additional, Woods, Jason C., additional, and Hopkins, Susan R., additional
- Published
- 2023
- Full Text
- View/download PDF
37. Comparison of the Quantitative CT Imaging Biomarkers of Idiopathic Pulmonary Fibrosis at Baseline and Early Change with an Interval of 7 Months
- Author
-
Kim, Hyun J., Brown, Matthew S., Chong, Daniel, Gjertson, David W., Lu, Peiyun, Kim, Hak J., Coy, Heidi, and Goldin, Jonathan G.
- Published
- 2015
- Full Text
- View/download PDF
38. Multi‐scale, domain knowledge‐guided attention + random forest: a two‐stage deep learning‐based multi‐scale guided attention models to diagnose idiopathic pulmonary fibrosis from computed tomography images
- Author
-
Yu, Wenxi, primary, Zhou, Hua, additional, Choi, Youngwon, additional, Goldin, Jonathan G., additional, Teng, Pangyu, additional, Wong, Weng Kee, additional, McNitt‐Gray, Michael F., additional, Brown, Matthew S., additional, and Kim, Grace Hyun J., additional
- Published
- 2022
- Full Text
- View/download PDF
39. Correction to: Toward clinically usable CAD for lung cancer screening with computed tomography
- Author
-
Brown, Matthew S., Lo, Pechin, Goldin, Jonathan G., Barnoy, Eran, Kim, Grace Hyun J., McNitt-Gray, Michael F., and Aberle, Denise R.
- Published
- 2020
- Full Text
- View/download PDF
40. Quantitative CT lung COVID scores: Prediction of rapid progression and monitoring longitudinal changes in COVID-19 pneumonia patients
- Author
-
Kang, Da Hyun, primary, Kim, Grace Hyun J., additional, Park, Sa-Beom, additional, Lee, Song-I, additional, Koh, Jeong Suk, additional, Brown, Matthew S., additional, Abtin, Fereidoun, additional, McNitt-Gray, Michael F., additional, Lee, Jeong Seok, additional, and Goldin, Jonathan G., additional
- Published
- 2022
- Full Text
- View/download PDF
41. Functional Airway Imaging Methods
- Author
-
Goldin, Jonathan G., Schoepf, U. Joseph, editor, Boiselle, Phillip M., editor, and Lynch, David A., editor
- Published
- 2008
- Full Text
- View/download PDF
42. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography
- Author
-
Khanna, Dinesh; https://orcid.org/0000-0003-1412-4453, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Cottin, Vincent; https://orcid.org/0000-0002-5591-0955, Brown, Kevin K, Chung, Lorinda, Goldin, Jonathan G, Matteson, Eric L; https://orcid.org/0000-0002-9866-0124, Kazerooni, Ella A; https://orcid.org/0000-0001-5859-8744, Walsh, Simon Lf, McNitt-Gray, Michael, Maher, Toby M, Khanna, Dinesh; https://orcid.org/0000-0003-1412-4453, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Cottin, Vincent; https://orcid.org/0000-0002-5591-0955, Brown, Kevin K, Chung, Lorinda, Goldin, Jonathan G, Matteson, Eric L; https://orcid.org/0000-0002-9866-0124, Kazerooni, Ella A; https://orcid.org/0000-0001-5859-8744, Walsh, Simon Lf, McNitt-Gray, Michael, and Maher, Toby M
- Abstract
Patients with systemic sclerosis are at high risk of developing systemic sclerosis-associated interstitial lung disease. Symptoms and outcomes of systemic sclerosis-associated interstitial lung disease range from subclinical lung involvement to respiratory failure and death. Early and accurate diagnosis of systemic sclerosis-associated interstitial lung disease is therefore important to enable appropriate intervention. The most sensitive and specific way to diagnose systemic sclerosis-associated interstitial lung disease is by high-resolution computed tomography, and experts recommend that high-resolution computed tomography should be performed in all patients with systemic sclerosis at the time of initial diagnosis. In addition to being an important screening and diagnostic tool, high-resolution computed tomography can be used to evaluate disease extent in systemic sclerosis-associated interstitial lung disease and may be helpful in assessing prognosis in some patients. Currently, there is no consensus with regards to frequency and scanning intervals in patients at risk of interstitial lung disease development and/or progression. However, expert guidance does suggest that frequency of screening using high-resolution computed tomography should be guided by risk of developing interstitial lung disease. Most experienced clinicians would not repeat high-resolution computed tomography more than once a year or every other year for the first few years unless symptoms arose. Several computed tomography techniques have been developed in recent years that are suitable for regular monitoring, including low-radiation protocols, which, together with other technologies, such as lung ultrasound and magnetic resonance imaging, may further assist in the evaluation and monitoring of patients with systemic sclerosis-associated interstitial lung disease. A video abstract to accompany this article is available at: https://www.globalmedcomms.com/respiratory/Khanna/HRCTinSScILD.
- Published
- 2022
43. Multi-scale, domain knowledge-guided attention + random forest: a two-stage deep learning-based multi-scale guided attention models to diagnose idiopathic pulmonary fibrosis from computed tomography images.
- Author
-
Wenxi Yu, Hua Zhou, Youngwon Choi, Goldin, Jonathan G., Pangyu Teng, Weng Kee Wong, McNitt-Gray, Michael F., Brown, Matthew S., and Kim, Grace Hyun J.
- Subjects
IDIOPATHIC pulmonary fibrosis ,DEEP learning ,COMPUTED tomography ,RANDOM forest algorithms ,RECEIVER operating characteristic curves ,INTERSTITIAL lung diseases - Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and usually fatal lung disease of unknown reasons, generally affecting the elderly population. Early diagnosis of IPF is crucial for triaging patients' treatment planning into anti-fibrotic treatment or treatments for other causes of pulmonary fibrosis. However, current IPF diagnosis workflow is complicated and time-consuming, which involves collaborative efforts from radiologists, pathologists, and clinicians and it is largely subject to inter-observer variability. Purpose: The purpose of this work is to develop a deep learning-based automated system that can diagnose subjects with IPF among subjects with interstitial lung disease (ILD) using an axial chest computed tomography (CT) scan. This work can potentially enable timely diagnosis decisions and reduce inter-observer variability. Methods: Our dataset contains CT scans from 349 IPF patients and 529 non-IPF ILD patients. We used 80% of the dataset for training and validation purposes and 20% as the holdout test set. We proposed a two-stage model:at stage one, we built a multi-scale, domain knowledge-guided attention model (MSGA) that encouraged the model to focus on specific areas of interest to enhance model explainability, including both high- and medium-resolution attentions; at stage two, we collected the output from MSGA and constructed a random forest (RF) classifier for patient-level diagnosis, to further boost model accuracy. RF classifier is utilized as a final decision stage since it is interpretable, computationally fast, and can handle correlated variables. Model utility was examined by (1) accuracy, represented by the area under the receiver operating characteristic curve (AUC) with standard deviation (SD), and (2) explainability, illustrated by the visual examination of the estimated attention maps which showed the important areas for model diagnostics. Results: During the training and validation stage, we observe that when we provide no guidance from domain knowledge, the IPF diagnosis model reaches acceptable performance (AUC±SD = 0.93±0.07), but lacks explainability; when including only guided high- or medium-resolution attention, the learned attentionmaps are not satisfactory;when including both high- and medium-resolution attention, under certain hyperparameter settings, the model reaches the highest AUC among all experiments (AUC±SD = 0.99±0.01) and the estimated attention maps concentrate on the regions of interests for this task. Three bestperforming hyperparameter selections according to MSGA were applied to the holdout test set and reached comparable model performance to that of the validation set. Conclusions: Our results suggest that, for a task with only scan-level labels available, MSGA+RF can utilize the population-level domain knowledge to guide the training of the network, which increases both model accuracy and explainability. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Reproducibility of Lung and Lobar Volume Measurements Using Computed Tomography
- Author
-
Brown, Matthew S., Kim, Hyun J., Abtin, Fereidoun, Da Costa, Irene, Pais, Richard, Ahmad, Shama, Angel, Erin, Ni, Chiayi, Kleerup, Eric C., Gjertson, David W., McNitt-Gray, Michael F., and Goldin, Jonathan G.
- Published
- 2010
- Full Text
- View/download PDF
45. Computer-aided Detection of Endobronchial Valves Using Volumetric CT
- Author
-
Ochs, Robert A., Abtin, Fereidoun, Ghurabi, Raffi, Rao, Ajay, Ahmad, Shama, Brown, Matthew, and Goldin, Jonathan G.
- Published
- 2009
- Full Text
- View/download PDF
46. Update on Radiology of Emphysema and Therapeutic Implications
- Author
-
Goldin, Jonathan G. and Abtin, Fereidoun
- Published
- 2009
- Full Text
- View/download PDF
47. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography
- Author
-
Khanna, Dinesh, Distler, Oliver, Cottin, Vincent, Brown, Kevin K, Chung, Lorinda, Goldin, Jonathan G, Matteson, Eric L, Kazerooni, Ella A, Walsh, Simon Lf, McNitt-Gray, Michael, Maher, Toby M, University of Zurich, and Khanna, Dinesh
- Subjects
2745 Rheumatology ,Immunology ,high-resolution computed tomography ,610 Medicine & health ,Bioengineering ,Neurodegenerative ,Autoimmune Disease ,Rare Diseases ,Rheumatology ,Clinical Research ,Immunology and Allergy ,Lung ,Cancer ,interstitial lung disease ,2403 Immunology ,screening and diagnosis ,Prevention ,Lung Cancer ,10051 Rheumatology Clinic and Institute of Physical Medicine ,imaging ,Brain Disorders ,4.1 Discovery and preclinical testing of markers and technologies ,radiation ,Detection ,progressive fibrosing ,2723 Immunology and Allergy ,Respiratory ,Systemic sclerosis ,Biomedical Imaging ,4.2 Evaluation of markers and technologies - Abstract
Patients with systemic sclerosis are at high risk of developing systemic sclerosis–associated interstitial lung disease. Symptoms and outcomes of systemic sclerosis–associated interstitial lung disease range from subclinical lung involvement to respiratory failure and death. Early and accurate diagnosis of systemic sclerosis–associated interstitial lung disease is therefore important to enable appropriate intervention. The most sensitive and specific way to diagnose systemic sclerosis–associated interstitial lung disease is by high-resolution computed tomography, and experts recommend that high-resolution computed tomography should be performed in all patients with systemic sclerosis at the time of initial diagnosis. In addition to being an important screening and diagnostic tool, high-resolution computed tomography can be used to evaluate disease extent in systemic sclerosis–associated interstitial lung disease and may be helpful in assessing prognosis in some patients. Currently, there is no consensus with regards to frequency and scanning intervals in patients at risk of interstitial lung disease development and/or progression. However, expert guidance does suggest that frequency of screening using high-resolution computed tomography should be guided by risk of developing interstitial lung disease. Most experienced clinicians would not repeat high-resolution computed tomography more than once a year or every other year for the first few years unless symptoms arose. Several computed tomography techniques have been developed in recent years that are suitable for regular monitoring, including low-radiation protocols, which, together with other technologies, such as lung ultrasound and magnetic resonance imaging, may further assist in the evaluation and monitoring of patients with systemic sclerosis–associated interstitial lung disease. A video abstract to accompany this article is available at: https://www.globalmedcomms.com/respiratory/Khanna/HRCTinSScILD
- Published
- 2021
48. sj-pdf-2-tar-10.1177_17534666211004238 – Supplemental material for The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis
- Author
-
Kim, Grace Hyun J., Goldin, Jonathan G., Hayes, Wendy, Oh, Andrea, Soule, Benjamin, and Shuyan Du
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified - Abstract
Supplemental material, sj-pdf-2-tar-10.1177_17534666211004238 for The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis by Grace Hyun J. Kim, Jonathan G. Goldin, Wendy Hayes, Andrea Oh, Benjamin Soule and Shuyan Du in Therapeutic Advances in Respiratory Disease
- Published
- 2021
- Full Text
- View/download PDF
49. sj-pdf-4-tar-10.1177_17534666211004238 – Supplemental material for The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis
- Author
-
Kim, Grace Hyun J., Goldin, Jonathan G., Hayes, Wendy, Oh, Andrea, Soule, Benjamin, and Shuyan Du
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified - Abstract
Supplemental material, sj-pdf-4-tar-10.1177_17534666211004238 for The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis by Grace Hyun J. Kim, Jonathan G. Goldin, Wendy Hayes, Andrea Oh, Benjamin Soule and Shuyan Du in Therapeutic Advances in Respiratory Disease
- Published
- 2021
- Full Text
- View/download PDF
50. sj-pdf-1-tar-10.1177_17534666211004238 – Supplemental material for The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis
- Author
-
Kim, Grace Hyun J., Goldin, Jonathan G., Hayes, Wendy, Oh, Andrea, Soule, Benjamin, and Shuyan Du
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified - Abstract
Supplemental material, sj-pdf-1-tar-10.1177_17534666211004238 for The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis by Grace Hyun J. Kim, Jonathan G. Goldin, Wendy Hayes, Andrea Oh, Benjamin Soule and Shuyan Du in Therapeutic Advances in Respiratory Disease
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.